NY Assembly Passes Bills to Improve MMJ Patient Access

New York’s Democrat-led Assembly passed two bills yesterday to improve patient access to medical marijuana under the state’s Compassionate Care Act. A.9510 would authorize nurse practitioners and physician assistants to certify patients for the program, while A.10123 would require the Department of Health to list registered practitioners’ information on their website.

A.9510 is sponsored by Assemblyman Richard Gottfried (D), who championed the Compassionate Care Act for years before it became law. The bill would not only permit PAs and NPs to certify patients but it would provide them the same training as physicians to become registered with the program.

“New York law allows NPs and PAs to prescribe the strongest and most dangerous controlled substances, but not medical marijuana,” Gottfried said in a press release. “Patients in need should not be denied access to critical medication just because they are treated by a PA or NP.”

The measure passed the Assembly 100-30 and has been sent to the Senate Health Committee.

A.10123, sponsored by Crystal Peoples-Stokes (D), aims to overcome the “major obstacle” for patients of finding registered practitioners. New York has certified 600 physicians under the program, but there is no publicly available list of those doctors.

“As a result, severely ill patients are forced to cold-call doctor after doctor in hopes of finding one, or try to find information through social media or other potentially unreliable sources,” the justification of legislation says.

The bill allows practitioners who do not want to be listed to opt-out. The list would be made available 60 days after it became law.

“I believe that current law – both the Compassionate Care Act and the Freedom of Information Law – requires that this list be public, as was the legislative intent. But apparently it needs to be spelled out.” Gottfried, a co-sponsor on the bill, said.

The bill has been sent to the Senate Health Committee.

End


Casey Hubbs: Extraction Lab Living

Casey Hubbs is the extraction team leader and lab manager at Orgrow, a licensed cannabis producer and processor based out of Moxee, WA. Casey’s story is one that illustrates exactly how the cannabis industry is made up of ordinary people who have made the extraordinary decision to jump head-first into an uncertain career. She recently joined our podcast host Shango Los for a discussion about how she got her job after majoring in herbal science, how she became the go-to source for advice about medical cannabis in her community, and what her average day in the lab consists of.  Listen to the podcast below, or scroll down for the full transcript!

Subscribe to the Ganjapreneur podcast on iTunes, Stitcher, SoundCloud or Google Play.


Listen to the podcast:


Read the transcript:

Shango Los: Hi there, and welcome to the Ganjapreneur.com podcast. I am your host, Shango Los. The Ganjapreneur.com podcast gives us an opportunity to speak directly to entrepreneurs, cannabis growers, product developers, and cannabis medicine researchers, all focused on making the most of cannabis normalization.

As your host, I do my best to bring you original cannabis industry ideas that will ignite your own entrepreneurial spark, and give you actionable information to improve your business strategy and improve your health and the health of cannabis patients everywhere.

Today my guest is Casey Hubbs. Casey is the cannabis extraction team leader and lab manager at Orgrow, a producer and processor in Moxee, Washington. Casey graduated from Bastyr University in 2008 with a degree in herbal science. She’s a long time master formulator of cannabis topicals, tinctures, and edibles and now brings those wide range of expertise to cannabis product development and manufacturing.

Often on this show, we focus on CEOs and internationally known cannabis researches, but when you get right to it though, it is the industry’s middle management that is the backbone of making sure quality cannabis products actually reach the store shelves. Today we are profiling Casey for everybody who’s curious about what it’s like, daily life in a production cannabis lab. Welcome to the show, Casey.

Casey Hubbs: Thank you, Shango. Thanks for having me.

Shango Los: Casey, we got to start at the top. You went and put in all that effort and got your degree in herbal science at Bastyr and then you go into a new industry that’s in chaos. Why did you choose to take a career chance and delve into the cannabis industry?

Casey Hubbs: Right.

Yeah, well when I was a senior at Bastyr, I ended up getting pregnant with my daughter, which was completely unexpected, and I did not want to continue school. I wanted to take time off for her, so I didn’t further my education and I didn’t want to dive right into a career because I wanted to be a momma. I had a childcare background, and so I decided that I would just take that a little further and start a business on a little island that I worked on and I did that for six years. I was actually really successful at it, but then once Isla started school I wanted to get back into the herbal medicine. I had started working with some people on cannabis. My best friend’s mom actually came down with a really aggressive form for rheumatoid arthritis, and she was a little worried about taking opiates and narcotics for her pain and wanted to start using cannabis, which ended up being really great for her because she also was doing chemo infusions to help knock out her immune system.

We started playing around with it and I kind of fell in love with it and then decided that because I was successful with her, it kind of opened up a door to these new people that I was meeting that were more involved in cannabis. One thing lead to another, and I decided to take a leap of faith. I had lot of student loans to pay off and put a couple resumes in and one thing lead to another and here I am today, working for a large tier-three grow.

Shango Los: You know, it is pretty powerful how when the people in the community find out that you know how to both process cannabis into a product that’s highly usable, but also you know how to recommend its usage for the patient, how suddenly you become the community expert and everybody wants to come to you.

Casey Hubbs: Yeah, definitely. I definitely had a leg up considering I knew how to work with plants and I knew how to extract plants and I knew about their constituents and their solubility. I didn’t know about activation for edibles and things like that in the very beginning, so I definitely had a large learning curve as far as cannabis. It was really, really exciting for me to see how it unfolded.

Shango Los: So. Go ahead, yeah. Sorry.

Casey Hubbs: No, that’s okay.

Shango Los: Right on. So there you are, you get your first job in cannabis. Of course, now you’re showered with a big salary and a title, right?

Casey Hubbs: Yeah, no. Actually I took a major pay cut to come put all my cards into cannabis, hoping that on the other side it was going to be successful and fruitful for me, and that I would have a career.

Shango Los: The other part that I know was the challenging part is that you were living on an island and then suddenly this job that you got was way on the other side of the state. What was that like for you? I mean, that must have been a hard decision to decide to move your family for a gamble in cannabis.

Casey Hubbs: Yeah, actually it was huge. I give a lot of credit to my husband for being supportive. The job that I ended up taking was in Moxee, and I grew up in Naches, Washington. So, one of the reasons that I could take this job here was that I had family support to help with my daughter. When we came over here we left our home, which I sometimes regret a lot as far as my daughter’s happiness and this sweet little community to back into the sticks. It’s been hard, but it’s been worth it, I think.

Shango Los: Right on, so cool. So we see the kind of struggle you went through to decide you wanted to try cannabis because you were excited about it and you had the skills for it.. So what were your initial responsibilities upon hire?

Casey Hubbs: I was hired at Orgrow to run their CO2 extractor, and to help them formulate. We were running an edible program at the time. We still are somewhat. We’re not offering as many edibles at this time, but we’re still continuing that program. To find out how to manipulate the oil, get it into pens, come up with a sell-able product, help them formulate tinctures and capsules, and other products as well.

Shango Los: You know, it really is a pioneering position because a lot of the corporate memory and business intelligence that is now readily available for states that are normalizing now, people like you in the early days of Washington were all in your own labs trying to figure out how to do this. Yeah, sometimes you guys were trading information via the internet or over drinks or something. But really, it was a whole bunch of mad scientists in 502 production labs trying to make the damn viscosity of the oil run for the cartridges, right?

Casey Hubbs: Right, right. Yeah. I have to tell you, I had a lot of really frustrating days. I thought I was going to come in here and it was all going to fall into place and I was going to be making tinctures all day, which I could do. Really it was beating my head up against the wall over and over and over. I had lots of frustrations, a lot of anger, a lot of second guessing why I had moved out here, and a lot of tears really, but I’m stubborn so I persevered. We definitely had some consultants come in and give us some direction, which was really helpful. Today we’ve kind of arrived at a place where I think we can be competitive and we do understand the oil. Finally, after about two years, we’re here.

Shango Los: Right on. So a lot of people, they think about the glamour of working in cannabis. Like, “Aw yeah. I’m gonna formulate, I’m gonna manufacture this stuff.” It’s gonna somehow look like it does in Disney, where you’ve got birds flying in the oil to you, a butterfly bringing you the edible.” It’s not like that. It’s kind of grimy, isn’t it? When you’re doing production things are getting tipped over, things are not being purged right, you have to start over again. I can imagine that that would be really frustrating trying to invent the wheel for the first time.

Casey Hubbs: Yeah, absolutely. We definitely went through a lot of product in the beginning. A lot of R&D. I think myself, as well as the company I was working for, was getting kind of frustrated with it. You’ve gotta worry about the color, you’ve gotta worry about the waxes, you’ve gotta worry about temperatures and parameters. It all feels like you’re losing your mind a little bit and then all of a sudden things start making sense and you have these moments of: “Oh my gosh. Right! Okay, that makes sense.” And you move on to the next step. It really is building it up piece by piece by piece.

Some people want to offer help, and other people don’t and they feel very proprietary about their information. They’ll give you bits and pieces and then the rest of it you put together like a puzzle.

Shango Los: Right on. I want to ask you one more question before go to the break. After the break we’re going to talk about some of your successes. But I want to put you on the spot right and ask you, will you describe one of your utter failures?

Casey Hubbs: Oh. I have a lot of them, I think. Yeah, I have one. We were developing, we were looking at topicals. We were playing with a chapstick. We had several samples set up for people, especially the owners to give to the board, which is what we did with all of our products. I was working with another gal that was in the kitchen with me. We made all these chapsticks and went and handed them out. The next day one of the owners, our general manager, CEO/base principal came back in and his lips were all red. He was like, “This didn’t work for me. My lips felt a little burned.” I think that was probably one of the biggest embarrassments. I spill a lot, so that happens in the lab, too. Anybody that’s working with this oil, especially winterized oil, knows that the minute you have one drop anywhere you have a complete disaster. That’s going to be there until somebody rubs enough dirt on it to be able to see it. It’s a very messy, dirty process.

Shango Los: That’s awesome. Thank you so much for sharing that story. We’re going to take a short break and be right back. You’re listening to the Ganjapreneur.com podcast.

As a cannabis entrepreneur, you know how challenging recruiting quality talent can be. Your day is already busy enough and yet there is an ever-growing pile of resumes on your desk and your team is begging you to hire more help. Hiring the right person can make a profound impact on your company. There’s no reason that you have to suddenly be an expert hiring manager. Not when there’s Viridian Staffing. Viridian Staffing recruits solely for adult use cannabis, medical marijuana and hemp companies, and those who service them. Viridian Staffing’s recruiters each have over ten years of experience and they will use that experience to recruit the kind of employees that will make you look good.

Whether you’re looking for master grower, extractor, grow room support, or trimming, Viridian can find an appropriate person in your area. They can even recruit administrative or graphic design professionals who may not need cannabis experience.

Because you are a startup, you may also need human resources help for a while. Viridian Staffing can make sure that your HR files are complete and keep you out of trouble with state and federal employment requirements. Because the cannabis industry is booming, cannabis recruiting companies are popping up all over the country. But good marketing does not mean good recruiting. Some of the recruiting shops that have opened are run by novices who do not yet have a thorough understanding of employment law and the complexities of hiring for cannabis. Don’t hire an amateur to find you a professional. Consider Viridian Staffing to make that stack of resumes disappear and complete your team with exactly the hire that you were hoping for. You can find out more at virdianstaffing.com – that’s v-i-r-i-d-i-a-n staffing.com. Now, back to the show.

Welcome back, you are listening to the ganjapreneur.com podcast. I am your host, Shango Los. Our guest this week is Casey Hubbs, extraction team lead and lab manager at OrGrow.

So you were such a good sport, Casey, before the break telling us about an abject failure of yours. Let’s turn it around and talk about some of your successes. You were describing in the first half about how startup environment and things were chaotic. Because Washington was one of the first states to normalize, you and other people like you in the state were trying to figure out how to do all this stuff for the first time. Do you remember the first moment when you had the realization that things were actually coming together?

Casey Hubbs: Yeah, I do. I do. It was only pretty recently, actually. About six or seven months ago we launched our Nova Cartridges, which is our vape oil, our CO2 extracted oil. We got picked up by a few stores across the state that wanted to carry our product exclusively. That was kind of my first hint at, oh wow we’re doing something right here. Then from that moment on I think my confidence became stronger and a little of the pressure was off so that I could really focus on some more of our techniques. A couple of months after that … I was really fighting with CO2 a lot. It just wasn’t doing what I needed it to do.

The market really wanted those concentrated, so shatters and waxes. I was having a really time with CO2 doing that. So I wanted to explore other options of extractions. Something that I was extremely with was ethanol. That’s what I learned at Bastyr was ethanol extracts. I was worried about hydrocarbons. It wasn’t something that I felt good about. I know there’s a huge culture and they make amazing extracts and with the parts per million (ppm) being monitored the way that they are and the analytics. It’s not that I don’t think it’s safe, it’s just that I didn’t want to make that product.

So we started playing with ethanol. I just did a ton of research and I had a lot of people who were willing to talk with me about a few of their processes. I put my own spin on it and all of a sudden our stuff was selling. People wanted it so much that I was running a two liter rotovap and I couldn’t keep up. So we ended up getting some more equipment through Genius Extractions based in California. We purchased their twenty liter rotovap. He came in, he meaning Richard, one of the brothers that’s involved in the company, came in and looked at our product and went, “Oh my gosh, that’s ethanol?” In that moment, I think I really married it. He said, “Wow, I’ve been across the country,” and he said, “I think you are probably top 5%.” In that moment I thought we’ve arrived, we’re good, I can let some of the pressure go. I think that’s what I feel most proud of right now.

Shango Los: You know, that’s a really good point, too. That kind of encouragement when you are doing your best, you know that the sale of the product that you’re developing has got a lot of people’s paycheck riding on it, you’ve gotta get encouragement from somewhere. Sometimes that encouragement comes from upper management. Sometimes it might come from a consumer who reaches out to you and says this is a damn good job. In this case it comes from a vendor who can give you a really educated opinion. That’s really great that that happened for you.

So I know that you have developed a whole line of products for OrGrow. What’s another one that you feel really proud of?

Casey Hubbs: I really like our capsules. I haven’t gotten to get so much into formulating, which is what I’m really excited about. We do edibles and stuff like I said before. We’re working on our concentrate department. That’s kind of where our main focus has been. We’re starting to look into other products as well, but our capsules, we take really great care to preserve our terpenes during our decarboxylation process. I really think that that has a huge effect on the delivery of our products. So the capsules, we have only done a small test market with them but the feedback has been very great for us.

Shango Los: That’s a good point. A lot of people don’t realize how important it is to preserve those terpenes. Some of the processing styles are really ruthless on the whole plant extract and suddenly your terpenes are gone, and terpenes are an essential part of true cannabis medicine. Even if you’re not taking it technically as medicine, if you’re taking it recreationally, recreationally is still relief medicine. It’s the terpenes, the aromatherapy of the cannabis plant that kind of sculpts what your high is like. So if you want the medicine to have any kind of personality, you’ve gotta preserve all that stuff.

Casey Hubbs: Yeah, absolutely. I believe in the entourage effect 100%. That’s one of the hard things about using ethanol, because ethanol is really known for depleting those terpenes in the products. We’re pretty careful about how we handle it and so far our feedback has been really, really good.

Shango Los: Right on. So for those who are listening who are coveting your job, give a little description of how your job has evolved from when you first started to now. I know that you’ve gotten some more responsibilities, but how did that progress go?

Casey Hubbs: So when I got hired on at OrGrow I was supposed to help them formulate products, understand the analytics behind the testing, and to run the CO2 extractor. That was it. But there was only about three of us full-time employees at the time, so it was all hands on deck. However, over the course of the last couple years or year and a half, we have lost a lot of people and we have implemented a lot more into what’s required of us. Now I prep all of the lab samples, the samples go out. For analytics we prioritize as far as extraction goes. The kitchen, help with the kitchen, proper homogenization. Everything from biotrack to seeing things get delivered out the door, so quality control. Communication between packaging and sales. Consulting for problems in the garden. Consulting with labs. Dealing with all of the vendors that we use for products. The list really goes on, and on, and on.

Shango Los: That really is the magic of middle management, right? You pretty much listed every aspect of a producer/processor expect for getting the investment capital and sales. So everything that’s happened in the building, you are a part of. I think there’s two important lessons about that. Number one: that working in a startup you’ve gotta be willing to wear a lot of hats and not be a prima donna about the part that you do. Also, for those who feel like they are an expert in one category, that if they really want to be successful at a startup it’s good to have things that you’re a master at, but also have some knowledge in all the other categories so that you can throw in some help in a jam.

Casey Hubbs: Absolutely, and be humble enough to go shovel snow if that’s what’s required of you.

Shango Los: Right on. That’s right, I forget you’re over there in eastern Washington. You actually have snow.

Casey Hubbs: We have snow. We had a lot of snow this winter, actually.

Shango Los: Right on. So again for the folks who are imagining themselves in your job, and this request may seem a little mundane to you, but I’m actually curious about it, walk us through a typical one of your days. It can’t always be like massive, awesome brilliance. Walk us through what a day of yours looks like.

Casey Hubbs: Right. Well, most of the time I’m running around like a chicken with my head cut off just shouting orders and trying to process. I get here and the first things I like to do is prioritize. So what I’ll do is I have boards that have Monday through Friday on them because our product, as it goes out, has to sit in quarantine for 24 hours. If you don’t have all your ducks in a line and your packaging and quality control isn’t finished, you can’t quarantine on time to get your sales out the door for delivery. Basically, that’s probably one of my number one priorities in the morning.

So I’ll come in, prioritize, see what needs to go out, make sure someone’s on packaging so that that can be finished. From there, I’ll check in to see where I am at in processing. So that’s the rotovap or short path or what’s being frozen or winterized and figure out what needs to happen with that. Then, also pick out what we’re going to run next and whether we have enough of one strain hitting the sativa, the hybrid, the indica coming down the pipe to make sure that we can fill all of the shelves with whatever people want, right. Then after that basically it’s just making sure that everything is labeled and converted in bio-track so that we’re following the LCB guidelines. Then pretty much wrap it up at the end of the day with clean up, which is pretty typical.

Shango Los: It’s interesting, because what you are describing are the non-sexy parts of the job. If we were to take out the word ‘cannabis’ and put in any other food product, it just sounds like you’ve got a job.

Casey Hubbs: Right. Yeah, it’s very, very similar to agriculture. I mean, that’s what it is. I think that all the time that this seems really glamorous and exciting, and cannabis is. There’s a lot of really cool things happening with cannabis and in the industry, but at the same time and at the end of the day, you’re right. When you remove the name cannabis it is just another profession.

Shango Los: Awesome. So we’re gonna to take another short break. When we get back we’re gonna talk about the gear in your lab. You are listening to the Ganjapreneur.com podcast.

The Ganjapreneur.com podcast is listened to by tens of thousands of cannabis entrepreneurs and enthusiasts every single week. These folks are most likely your target customers and we’d like to introduce you to one another. Our down to earth and information-rich commercial breaks can deliver your message to the cannabis business community and others who just find relief in getting high. If you want to reach out and connect with our audience in the most personal way that we can offer, go ahead and drop us an email at grow@ganjapreneur.com and we can talk about you becoming a commercial sponsor of the podcast. Thanks for listening and being part of the Ganjapreneur family. Now back to the show.

Welcome back. You are listening to the Ganjapreneur.com podcast. I am your host, Shango Los. Our guest this week is Casey Hubbs, extraction team lead and lab manager at OrGrow. Before the break we were talking about the things that can go right and wrong in the lab. We were talking about some of the products that you’re most proud of. I now that we have got gear heads who are listening to the show that are all like, “But what’s in her lab, man?” So let’s put that on the pedestal for a moment. Why don’t you break down the gear in your lab and any thoughts you might have about them.

Casey Hubbs: Sure. Right now as far as vacuum ovens, I’m running the TVO-5 with Cascade Botannical. I also have one of the smaller version of the Across International. Both of the equipment are super strong and both definitely have some weaknesses that I would probably wish to combine the two and make the perfect machine. But overall I’m actually pretty satisfied with Cascade. I really love that they’re a local company and their tech support is phenomenal.

As far as extraction equipment, right now we have a big 8×8 walk-in freezer that we’re doing a lot of our processing in. We recently purchased an extractor from Genius Extractions, we’re running the 20 liter. So far I’m really excited about. It has made our production go up by so much, and the quality of the product is still holding true to our smaller rotovap, which is a Buchi. I have run my Buchi for, oh my gosh, a little over a year and never had a hiccup with it. It has been a phenomenal machine.

So the CO2 extractor that we’re using is an Apeks. It’s been a work horse. We have had a lot of problems with it. As Apeks grew we kind of lost them on customer service a little bit. I don’t have anything bad to say about it, it actually put out a great product that I actually love for my pens. Great terpene preservation, but like I said we bought one of the first models so they did a lot of research and development in between the time period that we had purchased that and now and our machine is pretty much obsolete.

That’s about it for equipment. I do have a short path that I use. We’re using Hulabo and I’ve actually had some problems with, so we’re looking into the Heidolph system. Overall they’re all great, they’re all great piece of equipment. Nothing’s perfect, of course. There’s a lot of learning. The learning curve is huge, but I’m pretty happy with all of them.

Shango Los: You know, one of the things that you mentioned that I think is important to point out is how quickly the revs of these products are coming. Because the market is so new and a lot of these products have been developed specifically for cannabis, some haven’t. But the ones that haven’t, they are now being reapplied to this new industry. So they put out a new product, they get all this new feedback, and suddenly they’re like, “Oh my gosh. We’ve gotta upgrade this.” So now there’s a new version of it, but you just bought the old one eight months ago or whatever. I think that’s a really important thing both for, entrepreneurs who are going to set up a lab to remember, and for companies that are designing these, that everyone should be prepared for rapid development of these new technologies. It is a petri dish of creativity and feedback right now.

Casey Hubbs: Yeah, it is. Absolutely. I would say that one of the best ways to keep yourself informed if you are looking at purchasing equipment is to go to the shows. I have gotten so much information from going to shows where the equipment is set up. Even analytical labs, they have a lot to say about the product that they’re seeing. Everything is private, but they still can talk about the different equipment. That was really helpful for me.

Shango Los: Right on. So let’s wrap up with talking about the actual lab management. It is one thing to be an extraction technician and it’s something else to be responsible for that the lab is actually functioning. It’s a higher level of organization that’s gotta take place. What are some of your experiences with actually managing the lab that are worth remark?

Casey Hubbs: Right. That’s actually been a really hard transition for me. I came in kind of in control of the lab because really the investors that I worked for, the company, was non-marijuana people. So I had marijuana knowledge, but needed to sell them on it. Basically tell them, okay this is what I see, this is what we should do and they were super, super supportive of that. But I also made a lot of friends in those first beginning stages, along with coworkers who were helping me. So I think going from being friends to being professionals was a pretty hard transition. Also, the biggest thing is making sure that you’re tracking. You have to track everything. It’s easy to go in there and make products and R&D on different things that you’re developing, but then tracking that and making sure that you’re being conscientious of how the company is spending money on you and the people that are working under you is pretty stressful. It’s definitely a different game.

Shango Los: Right on. Cool, well thanks for explaining that. That’s all the time we’ve got. Time for us to wrap up. Casey, thanks so much for being on the show. It’s really nice to hear a day in the life of somebody who’s really actually doing it and putting the cannabis on the shelves, so thanks for sharing your story.

Casey Hubbs: Thank you so much for having me, Shango.

Shango Los: Casey Hubbs is the cannabis extraction team leader and lab manager at OrGrow, a producer and processor in Moxee, Washington. You can follow Casey’s Instagram for lab photos at @herbal_majesty.

You can find more episodes of the Ganjapreneur podcast in the podcast section at Ganjapreneur.com and in the Apple iTunes store. On the Ganjapreneur.com website you will find the latest cannabis news, product reviews, and cannabis jobs updated daily, along with transcriptions of this podcast. You can also download the Ganjapreneur.com app in iTunes and Google Play.

For info on me and where I will be speaking, you can go to shangolos.com. Do you have a company that wants to reach our national audience of cannabis enthusiasts? Email grow@ganjapreneur.com to find out how. Today’s show was produced by Michael Rowe. I am your host, Shango Los.

End


Stoned Sheep Cause Chaos in Quiet Welsh Village

In a truly unique story out of South Wales, a flock of “stoned sheep” is reported to have wandered through and caused havoc throughout Rhydypandy, a small countryside village in the Swansea valley.

The sheep are believed to have eaten remnants from an illegal cannabis grow op that had been dumped just outside of town, local sources report.

According to county councilor Ioan Richard, sheep have been “roaming the village,” causing havoc and upsetting citizens. “They are getting in people’s gardens and one even entered a bungalow and left a mess in the bedroom,” said Richard.

Richard, who has been publicly grappling with illegal dumping in his area, also said that if the mess wasn’t cleaned up quickly, “we could have an outbreak out of psychotic sheep rampaging through the village.”

A Swansea County spokesperson said that the county acted swiftly in cleaning up the illegally-dumped refuse, but wasn’t sure whether or not any sheep had actually consumed some of the cannabis.

“The fly-tipped [illegally-dumped] waste has now been removed, but we’d urge anyone with information about who may be responsible to contact either ourselves or South Wales Police. Fly-tipping has a negative impact on local communities, so we’re doing all we can to both prevent it and clean up as quickly as possible at known hot spots. We also investigate all cases of fly-tipping and will take enforcement action if there’s sufficient evidence.”

It seems worth noting that public officials in this scenario appear most concerned with the dumping violation rather than the illegal cannabis grow — a sign of shifting public opinion.

End


House Speaker Paul Ryan Believes CBD Law Will Pass Congress

House Speaker Paul Ryan believes there may be enough Congressional support to pass a law that would legalize CBD oil for the treatment of childhood seizure disorders, according to a Channel3000 report.

Ryan first endorsed legislation to legalize CBD oils in 2015 when he signed on as co-sponsor for Rep. Scott Perry’s (R-PA) bill, which seeks to remove hemp and CBD-rich cannabis products (with less than 0.3 percent THC) from the definition of marijuana under the Controlled Substances Act. The bill has stalled in recent months, but Ryan said he thinks they will ultimately get the support needed to send on the proposal.

“It’s going to take a while to get through the legislative process just like any other bill in Congress,” Ryan said. “This oil does not have THC in it, so therefore it really shouldn’t be lumped into the category of anything close to legalization of marijuana and that’s the confusion that typically surrounds the issue.”

“Once you get people through the confusion that surrounds this issue, I think people agree this is a good thing and there’s no reason to oppose this,” Ryan said.

While it’s heartening to see enthusiasm for cannabis reform on the federal level — particularly among members of the GOP — it is worth noting that CBD-specific legislation is not the most ideal of legalization laws. In fact, treatments with CBD-only products have proven to be significantly less effective than whole-plant therapy, though elected officials either don’t care or remain unconvinced of this fact.

End


U.S. House Seeks Tightening of Washington D.C. Cannabis Restrictions

The GOP-controlled House of Representatives is seeking stronger restraints on Washington D.C.’s ability to reform marijuana laws, Tom Angell reports for Marijuana.com.

Current law says the District is not allowed to spend annual appropriations funding on “any law, rule, or regulation to legalize or otherwise reduce penalties associated with the possession, use, or distribution of any schedule I substance.” This means that the District could technically spend money on marijuana reform if it was sourced from outside of a federal appropriation bill.

New language proposed in the House Appropriations Committee, however, changes the restrictions from blocking only appropriated money to any funds that are “available for obligation or expenditure by any officer or employee of the District of Columbia government” — this means that zero government-sourced funds, even contingency reserve funds, could be spent on establishing local cannabis regulations.

Washington D.C. voters passed a referendum to legalize and regulate recreational cannabis in 2014 with a 70 percent super majority of the popular vote. City Council member David Grosso wrote in response to the Republican effort to squash the District’s autonomy, “I wish they would get a life and let D.C. elected officials … do our jobs.

Unsurprisingly, presidential preference lands on the side of D.C. autonomy, according to a statement issued yesterday. “The Administration strongly supports home rule for the District and the President has long called for authority allowing the District to spend its own local taxes and other non-Federal funds without congressional approval.”

End


Nasdaq Denies MassRoots Application; Company Plans Appeal

The Nasdaq has denied the application of MassRoots, the social media platform designed for cannabis enthusiasts, to have its shares listed and traded on the stock exchange, according to a Denver Post report.

MassRoots CEO Isaac Dietrich said he has asked for a written denial instead of voluntarily withdrawing the application and plans to appeal to the Nasdaq Listing and Hearing Review Council and, if necessary, to the Securities and Exchange Commission.

Currently MassRoots is traded “over the counter,” (OTC: MSRT) subjecting them to less stringent regulations than the “big league” exchanges. Yesterday, the same day the rejection was announced, those shares dropped more than 18 percent, closing at 74 cents. Their all-time high was $2.59 on April 21, 2015.

Dietrich said Nasdaq officials seemed hesitant about allowing MassRoots onto their exchange during a meeting last month.

“I don’t think they want to be trailblazers on this,” he said.

The market requires specific financial liquidity criteria which also includes language that allows them to block a listing “if necessary to protect investors and the public interest.” Dietrich says there is some hypocrisy at work if his application is being denied because his business is marijuana-centric. British bio-pharma firm GW Pharmaceuticals is currently listed on the American exchange and its cannabis-derived epilepsy and multiple sclerosis drugs are being considered for Food and Drug Administration approval.

“Right now, on the OTC, a significant portion of investors are unable to trade our stocks … and the institutional investors tend to stay away from the OTC,” Dietrich said in the Denver Post report. “It would’ve been a tremendous victory for the entire industry.”        

End


Oregon Medical Growers Hope to Go Unnoticed in Rural Residential Land

Many medical cannabis growers in Jackson County, Oregon appear to be opting out of a growing license that’s now required to continue cultivating cannabis on rural residential land. Individuals caught growing with a license could face fines of up to $10,000.

According to a Mail Tribune report, however, county officials said they won’t be actively hunting down illegal growers. Rather, they will only investigate cases based on reports of a suspected illegal grow, or complaints from a neighbor.

Only seven people have filed applications with the county for a license to continue growing on rural residential land — Jackson County allows cannabis grows on farm-use and forest land.

“Some people may have moved onto lawful property. Maybe some decided not to grow,” said Jackson County Development Services Director Kelly Madding. “I also think there are people who understand we do enforcement on a complaint basis and they’re waiting to see if we come knocking on their door.”

Growers who have complaints filed against them will be given the opportunity to apply for a permit. Fines and other penalties will kick in if the grower refuses to seek a permit, said Madding.

End


Panama President Signs Law Legalizing Medical Marijuana

Ganjapreneur has received a tip that the President of Panama, Juan Carlos Varela, signed a law on May 19 that could legalize and regulate medical marijuana throughout the country.

We are still working on a complete translation of the document, but the law (written in Spanish) regulates “the activities and use of controlled substances for medical and/or scientific purposes.” Such substances must be prescribed by medical professionals and dispensed by pharmacists with the appropriate authorization.

The national change will apply universally throughout Panama and all of its territories, even extending to airlines, shipping lines and boats flying the Panamanian flag.

Under the new law, the Department of Pharmacies and Drugs will be in charge of implementing the changes, which will include establishing licenses and permits for the importation, exportation and distribution of the controlled substances.

In the past, Panama officials have been loudly outspoken against the relaxation of drug laws — recent international trends, however, demonstrate that global enthusiasm for continued drug prohibition appears to be dwindling. At the United Nations General Assembly Special Session on Drugs this year in New York, Canada, Mexico and Germany all announced major reforms to their marijuana laws.

We will release more information as it becomes available, but we are excited to see another domino fall in the international fight against marijuana prohibition.

End


Michigan Court of Appeals Upholds MMJ Law Definitions

Michigan’s Court of Appeals ruled against two men last week who had appealed their drug charges using the state’s medical marijuana laws as their defense. The ruling effectively puts an end to dispensaries in the state and severely limits how patients can obtain medical cannabis.

In 2010, Ryan Bylsma pleaded guilty to a high-court misdemeanor of marijuana possession and maintaining a drug house for his collective grow operation. In 2013, David Overholt was charged with delivery or manufacture of marijuana after his dispensary, Mid-Michigan Compassion Club, was raided by police. He pleaded no contest to those charges.

Both of the Grand Rapids men argued that they acted legally under Section 8 of the medical marijuana law, which allows patients to grow their own cannabis, or for an approved primary caregiver to dispense marijuana to up to five patients. The court ruled that neither man met the Section 8 definition.

In Bylsma’s case, the appeals panel said many of his clients had designated themselves or others as primary caregivers, and that he cultivated marijuana for other non-patient caregivers that did not need medical marijuana.

Matt Hoffman, a self-described expert on Michigan’s medical marijuana industry, calls the law itself “confusing” and says the court’s ruling will push patients into the black market.

“I don’t think that’s the intention of the act, to make people who are law-abiding citizens break the law to access something the law said they could access,” Hoffman said in a WoodTV 8 report.    

Last year a bill providing regulations for “marijuana provisioning centers” passed the state House of Representatives 95-11. It is currently with the Senate Committee on Judiciary.

End


‘Altered State’ Oakland Museum Exhibit: Photos and Review

Altered State, a new exhibit at the Oakland Museum of California, is a first-of-its-kind exploration through the many facets of cannabis.

Spanning over 3,700 square feet on the museum’s ground floor, Altered State is a quirky mix of vintage paraphernalia, art, historical timelines, live pot plants and photographs of pot-smoking celebrities and others who have played and continue to play a significant part in California’s dance with cannabis.

California’s role in the rise of cannabis’ status is significant from both historical and modern perspectives. In 1996 it became the first state to legalize medical marijuana and, while its path has been uneven since then, it continues to help shape the legal and cultural climate of the plant.

While the exhibit is focused on California, it’s also significant for the industry at large. Visitors can follow the various ways cannabis has been experienced and perceived throughout its history. Placards and overblown photos meld with interactive art to create displays that are both informational and tactile.

A confessional booth allows visitors to write out their secret feelings about marijuana. “I’d rather smoke pot than make love,” one person scrawled, while another detailed how cannabis helped a loved one through cancer.

Another section focuses on spirituality and how it has been used in various world religions. Butcher block is taped on the wall so visitors can weigh in on one of cannabis’ most debated questions: does it enhance or hinder spiritual development?

Other exhibits look at cannabis’ effect on youth, the rise of the medical industry and its economic impact.

Altered State runs through September 25, 2016.

AlteredState1
Natalia Thurston, an attorney for the cannabis business community and consultant for Altered State stands under her selfie at the exhibit.
AlteredState2
Altered State is the first museum exhibit to include live plants in their display.
AlteredState3
Hemp has nearly as complicated a history as cannabis.
AlteredState4
Each section of the exhibit explores a different facet of cannabis.
AlteredState5
Photos and captions provide a timeline of cannabis both throughout the world and in California.

End


NYPD Commissioner Says Most City Drug Violence is Marijuana Related

New York City Police Commissioner William Bratton continues to rally against marijuana legalization; attributing “most of the [drug] violence” seen within the city to marijuana trafficking.

“I have to scratch my head as we see many states are wanting to legalize marijuana or liberalization of policies,” Bratton said in an interview yesterday with AM 970’s John Catsimatidis, host of National Edition. “Here in New York, the violence we see associated drugs, the vast majority of it is around the issue of marijuana – which is ironic considering the explosion of the use of heroin now in the City.”

This isn’t surprising. He made a similar statement in 2014, in which he associated “gang murders” with the illegal marijuana market.  That following year — less than a year after he and Mayor Bill De Blasio announced people would stop being arrested for low-level possession — Bratton said that “under no circumstances  would there be any more concessions regarding the Big Apple’s pot policies.

The city’s new policies are, so far, keeping marijuana arrest rates down — almost 50 percent fewer from October 2014 through June 2015 from that same period the previous year. De Blasio has not come out in favor of legal marijuana, but said he was watching Colorado and Washington State to see how it plays out.

Bratton is set to meet with chiefs from 75 other departments from the US and Canada this week during a Major Cities Chiefs Association conference.

End


Nebraska MMJ Advocates May Delay Legalization Efforts Until 2018

Medical cannabis advocates in Nebraska have announced they will not follow through on plans for petitioning to get medical marijuana legalization on the ballot this November. Instead, they plan to make a push for the 2018 election season, according to a Lincoln Journal Star report.

“We just can’t count on the Legislature,” said Shelley Gillen, whose son Will suffers from epilepsy and could be helped by medicinal cannabis. “We’ve been doing this since Will was 11. He’s now 14. So we’ve been through it three legislative sessions.”

The Nebraska legislature struck down a bill this session that, if passed, would have established an extremely restrictive (though potentially life-saving) medical marijuana program. The bill, LB643, would have legalized cannabis in pill, oil, or liquid forms for patients suffering from very specific conditions and who have received a doctor’s recommendation.

The bill’s sponsor, Sen. Tommy Garrett (R-Bellevue), said he was heartbroken by its defeat because he had convinced activists earlier in the year to abandon plans for a petition drive. “I really thought we had a great chance of getting [the bill] passed,” Garrett said.

Now, according to Garrett, a petition drive to get medical marijuana legalization on this November’s ballot would cost somewhere between $700,000 and $1,000,000 — that’s too much money, with not enough time in advance.

Garrett will face re-election this year. If he returns to the legislature, he plans to reintroduce the bill next session. “We’re going to keep fighting the fight,” he said.

End


Vancouver Licenses its First Medical Cannabis Dispensary

The Wealth Shop will be the first “legal” marijuana dispensary to open under Vancouver, British Columbia’s new municipal bylaws regulating the sector, according to the Globe and Mail report.

Medical marijuana is permitted under Canadian law but it only allows about 24 industrial-scale grows. Licensed growers are allowed to sell dried marijuana and bottles of oil through the mail but dispensaries and “compassion clubs” operate outside of the law.

Vancouver is the first province to put forth a set of bylaws licensing dispensaries — there were as many as 100 operating when the city council began drafting the bylaws last spring.

Under the new rules, for-profit dispensaries require an annual $30,000 licensing fee paid to the city. Compassion clubs, which are run by a non-profit and offer additional health services such as acupuncture, require a $1,000 annual licensing fee. The shops will continue to operate outside of Canadian federal law — which is likely to change next spring as lawmakers will consider legalizing cannabis for recreational use.

The province is expected to approve two other shops imminently, while 12 others have made it to the second of three licensing stages. Officials shut down 30 shops for operating without licenses and 61 others remain subject to enforcement under the new rules. In all, 139 shops were issued $250 tickets.

Malik Sayadi, a hiring representative for The Wealth Shop, said he and his partners decided to wait for the licensing process and gain support from the community rather than open up without approval.

“Instead of trying to become the first ones there, we just went through all the proper procedures and worked closely with everybody that wanted us to work with them,” he said.

End


Illinois Decriminalization Bill Heads to Gov. Rauner for Signature

The Illinois legislature has approved a decriminalization bill that changes the penalty for possessing personal amounts of cannabis from a criminal offense to a civil one, punishable with fines instead of potential jail time, The Chicago Tribune reports.

The bill compounds on a proposal from last year that was ultimately vetoed by Gov. Bruce Rauner for being too lax on marijuana users. As per recommendations from the governor, this year’s proposal lowers the amount of cannabis that can be carried (without facing criminal charges) from 15 grams to 10 grams, and increases the fine for such an offense from between $55 and $125 to between $100 and $200.

The governor is expected to sign the bill, though has said that he believers there are more pressing issues facing the Illinois legislature.

“Illinois is long overdue for creating marijuana policies that treat our residents more fairly and free law enforcement up for more serious crime,” said bill sponsor Rep. Kelly Cassidy (D-Chicago) in a statement. “We should not spend our resources arresting and jailing people just for the possession of a small amount of marijuana.”

Current Illinois law calls the possession of 10 grams of cannabis a class B misdemeanor, punishable with up to six months of jail time and fines as high as $1,500.

The law also changes Illinois’ current zero-tolerance policy in regards to drugged driving, establishing a system to regulate driving under the influence of marijuana that would be similar to those currently being used in Washington and Colorado.

End


Congress Passes Bill Granting Veterans Access to Medical Marijuana

U.S. veterans will finally be allowed access to medical cannabis in states where it is legal following Congressional approval of the Military Construction and Veterans Affairs bill, the Military Times reports.

Rep. Earl Blumenauer (D-OR) offered the amendment to the spending bill prohibiting the VA from using funds to enforce policies preventing doctors from recommending marijuana to their patients. The amendment passed 233-189 in the House; the Senate is expected to pass the full legislation, which was approved by the House 295-129.

“The death rate from opioids among VA health care is nearly double the national average,” Blumenauer said during a debate on the floor. “From what I hear from veterans is that medical marijuana has helped them deal with pain and PTSD, particularly as an alternative to opioids.”

VA researchers released a report last February noting that there have yet to be any “gold standard” studies on using marijuana to treat PTSD but referenced a 2014 study of 10 participants that concluded THC was “safe and well tolerated by patients with chronic PTSD.”

The VA report goes so far as to suggest that “marijuana can be harmful to individuals with PTSD,” urging doctors to refer patients who use marijuana to a substance abuse disorder specialist.

Medical marijuana is legal in 23 states, with another 17 allowing physicians to prescribe marijuana oils. PTSD is an approved condition for treatment with cannabis in 14 of those states.

End


Washington LCB Adopts Emergency Rules on Pesticide Levels, Tax Payments & Product Recalls

The Washington State Liquor and Cannabis Board (LCB) issued an email yesterday informing of upcoming changes to three different facets of Washington’s cannabis regulations: action levels for disallowed pesticides, cannabis excise tax payments, and rules regarding marijuana product recalls.

The proposed action levels for disallowed pesticides will address the LCB’s current zero tolerance policy. Action levels dictate how much residue of a forbidden pesticide is allowed in a licensed production facility before suffering legal penalties. A zero tolerance policy is considered to be unfair because even the smallest trace of forbidden chemicals — many of which can be found in small quantities in nature or in most typical laboratories — could result in severe penalties. The LCB’s proposed action levels are based on research performed by the Oregon Health Authority and mirrors similar rules established in Oregon.

Another emergency rule change addresses the generally cash-based nature of legal cannabis. The proposal would require cannabis companies to issue their excise tax payments using “means other than cash.” The rules take effect July 1, 2016, after which licensees who typically pay in cash must start making excise tax payments using other means, such as “E-file, cashier’s checks, money orders, or personal/business checks.”

Product recalls have surfaced in legal cannabis as an unfortunate but important circumstance to consumer safety. According to the LCB’s email, the proposed product recall procedures “provide the ability to identify and remove products that have been found to pose a risk to public health in a fast and efficient manner. In addition the rules also provide licensees with the ability to withdraw products for reasons that are not related to public health risks, such as faulty packaging or aesthetic purposes.”

There will be a hearing about the product recalls proposal on July 13th. The meeting, during which public comment is encouraged, will start at 10 a.m. in the LCB Board Room in Olympia.

End


Michigan Petition Laws May Thwart Legalization Efforts

The push by advocates in Michigan to put a marijuana legalization initiative on November ballots is being hampered by a Board of State Canvassers stalemate, forcing the two public interest groups behind the measure to gather thousands of signatures by the June 1 deadline.

The stalemate focuses on petition signatures over 180 days old. One of the requirements for a signature to be considered valid dictates that the signee is a legitimate voter in the state – something that could change within 180 days. Under the current system, the board requires signatures over 180 days be confirmed by the petitioners via signed affidavits. MI Legalize, one of the groups behind the initiative, has 160,000 such signatures and asked the board to simplify the confirmation requirements.

Jeffrey Hank, MI Legalize Chairman, proposed matching the signatures in question with the Department of Elections’ qualified voter file, which he says would quickly and simply validate the signatures.

“We’ve spent almost a million dollars collecting over 300,000 signatures,” Hank said in the AMI Newswire report. “All they have to do is adopt the qualified voter list to verify those signatures over 180 days old, and the situation will be fine.”

The four-person Board of State Canvassers, comprised of two Republicans and two Democrats appointed by Republican Gov. Rick Snyder, has held a series of votes on the measure but the result has always been a 2-2 deadlock. The Board of Elections cannot give the groups the list without approval by the Canvassers Board.

Norm Shinkle, a Republican board member, says the public interest groups are asking him and his colleagues to bail them out.

“We’re here today because there are people in the field who have failed to gather their signatures in the allotted time that has been with us for 30 years,” he said in a Detroit News report. “We should not be changing the rules in the middle of the game.”

Hank says forcing them to track down 160,000 people to validate their signatures is “impossible” in just two weeks. His organization is planning a rally at the capitol in Lansing on Friday hoping to raise additional funds and add to his signature totals for the final drive.

End


Mowgli Holmes: Creating the Cannabis Family Tree

Mowgli Holmes is the co-founder and Chief Science Officer of Phylos Bioscience, a cannabis genomics firm whose mission includes telling the evolutionary story of the cannabis plant. Mowgli recently joined our podcast host Shango Los for a discussion of what his research has uncovered to date, how long ago humans began to cultivate cannabis, how Phylos Bioscience is building a 3D map of cannabis genomics, and more. Listen to the full interview below, or scroll down for the transcript!

Subscribe to the Ganjapreneur podcast on iTunes, Stitcher, SoundCloud or Google Play.


Listen to the podcast:


Read the transcript:

Shango Los: Hi there, and welcome to the Ganjapreneur.com podcast. I am your host, Shango Los. The Ganjapreneur.com podcast gives us an opportunity to speak directly to entrepreneurs, cannabis growers, product developers, and cannabis medicine researchers, all focused on making the most of cannabis normalization. As your host, I do my best to bring you original cannabis industry ideas that will ignite your own entrepreneurial spark and give you actionable information to improve your business strategy and improve your health and the health of cannabis patients everywhere.

Today my guest is Mowgli Holmes, co-founder and chief science officer of Phylos Bioscience. Mowgli is a molecular and evolutionary biologist. He has a PhD from Columbia University, where he was a National Research Service Award fellow. He’s a founding board member of the Cannabis Safety Institute and the Open Cannabis Project, and is a chair of the Oregon State Cannabis Research Task Force.

Mowgli and his team and Phylos are focused on mapping the cannabis plant family tree. They have created a 3D map of the cannabis genetic family in order to better understand the traits of individual cultivars and empower us to create crosses that can provide targeted relief to humans.

Welcome to the show, Mowgli.

Mowgli: Thank you, Shango.

Shango Los: To get us started, in order to get a snapshot of the timeline that we’re going to be discussing today, what’s the farthest back that we can claim that humans knew about the cannabis plant and at what point can we show evidence that humans were trying to domesticate the plant by some sort of intentional relationship with it?

Mowgli Holmes: All of the evidence that we have points to cannabis being domesticated right when we first domesticated any plants, which is about 10,000 years ago. We think that the first origin of domesticated cannabis was, you know, somewhere between 8 and 10,000 years ago, somewhere in Central Asia. The oldest actual sample that we have is a 2,700 year old sample that was discovered in a shaman’s tomb that was dug up in the Gobi Desert.

Shango Los: How do you go about getting this kind of material? I’m sure that with some of the hybrid stuff that’s happening modern, you can ask friends or go to a dispensary, but how do you get your hands on cannabis from a shaman’s tomb?

Mowgli Holmes: I mean, for us, the collection process has been so fascinating and difficult and complicated, and there’s all these different layers of historical sample. You know, we’ve got a lot of modern dispensary stuff, and then we’ve got a lot of second and third gen hybrids that we’ve collected by just reaching out to our broader network of connections in the cannabis industry and tracking down old breeders and collectors and just collecting really all over the world and having our partner labs in different states and even different countries extract DNA for us. We’ve got samples of the early first gen hybrids, which were the first time that people ever crossed land races together, the classics like Maui Wowie and Panama Red and Kona Gold. Those are some of the oldest ones that we have that are hybrids.

Then, going back and going to lots of other countries, I think we have samples from 16 different countries now. We’ve been able to collect a lot of land races, but then getting the really old stuff has been a process of working through our museum connections and reaching out … at the big plant museum collections where people have dried plant material that has been preserved for hundreds and hundreds of years. That particular old sample from China right now is in the Turpan Museum. We’ve been trying for a year and a half to get ahold of it.

We know some of the people who were on the paper that first described it. One of our collectors travels to China regularly. We think we’ll have a sample in the next few months. It’s very difficult coordinating international exchange of samples that until you extract the DNA are illegal, with people in Northern China. Many of them don’t speak English. It’s just a very complicated process. That sample is sitting there. In fact, there’s a little bit of DNA from it in the archive at GW Pharmaceuticals. That’s another potential avenue that we’re working on.

Shango Los: I can imagine how helpful the museum has been to give your project some more cred in trying to get a sample like that from China. I know that I’m really showing my hand as being a genetics novice with this next question, but those genetics are so old, are they still viable or do they break down and degrade with time? I don’t know how much I’ve learned from Jurassic Park is real, right?

Mowgli Holmes: Yeah, I mean, basically dry material can never produce living material with plants. There’s just no way. The slightest bit of living tissue could, in theory, be coaxed into a new plant, though honestly a lot of things need to be done correctly for that to work. If you go into even a dispensary and you get some stuff that was cured last week, it’s dead. It’s not going to grow. All we can do is analyze the DNA. We’re never going to be able to grow those plants. It’s the same with dinosaurs. You find fragments of their bones or whatever and you can often get DNA and analyze the DNA, but you’re not going to grow a live dinosaur.

Shango Los: Yeah, much to most everybody’s disappointment.

Mowgli Holmes: I know. People keep asking us to bring back Panama Red with some kind of Jurassic Park-style technology. I don’t think it’s in the cards.

Shango Los: All right, so that was looking backwards. You’re gathering these samples that are ancient through your museum relationships, and the stuff that’s several decades old you’re getting from different collectors and secret friends around the world who have kept them reliable. Then, of course, the modern hybrid stuff is pretty easy to get. Now, these seeds and these genetics all somehow tend to find their way to Northern California, right, where they thrive and are crossed and recrossed. If I understand how your mapping project works correctly, you actually have to unravel these crosses so that you can plot them out into your beautiful 3D graph. To what extent is it even possible to unravel the crazy soup of crosses and recrosses that are sitting in Northern California so that you can make sense of it?

Mowgli Holmes: I mean, it’s a scientific parable, it really is. I mean, the galaxy, our map of the cannabis population, I mean, if you played with it, you know it is a very tangled structure. That is the structure. That structure in the galaxy doesn’t represent any untangling of the actual structure. That is the tangled structure right there. As we start to fill in more and more samples, as we fill in more older, interesting, land raise type samples, I think some more clarity will be added. As we fill in more modern samples, it’ll just get messier and denser because each position in the galaxy is the actual genetic position that it has. When you have complicated back-crossing and selfing and hybridization, you end up with these weird clusters. We positioned all those dots in the correct relationship to each other in genetic space as well as can be done. The mess that you see there reflects the actuality of how tangled and confusing the population is. It’s just complicated.

As you go back in time, things will clarify. Pretty soon, we’ll be able to tell people things like, “Your sample is 30% Thai and 15% Colombian heritage.” It’s just like what 23andMe does for humans. If you go to 23andMe, you can order a genetic testing kit and then they’ll sequence your DNA and they’ll do an analysis very much like we do and they’ll tell you, “Your ancestry is 15% Native American and 5% Dutch. Your grandfather who told you that he was from Holland was actually from Namibia, sorry.” People find out all this interesting stuff. We’re using a lot of similar technology, so we’ll be able to tell people a lot of similar things about their plants.

Shango Los: Let’s nerd out on the galaxy tool for a minute. Most of the listeners probably have not seen it yet, and to my novice eyes what it looks like is this beautiful computer rendered 3D architecture that you can move around and focus in on and come back out and it creates a data space that shows the relationships of all of these different genetics. In what way, as a scientist, does it help you to be able to visualize this as a 3D tool instead of just doing it the traditional way with paperwork?

Mowgli Holmes: Right, well so that tool is actually just a super fancy version of what population geneticists actually used. Lots of people have asked us why it’s not a tree. It turns out that trees show branching separation. The branches branch and separate from each other, and that is a good picture of how species separate. Then, when they can’t inter-mate anymore, they go off on their own branches and they’re separate forever and they keep branching. Evolutionary trees show a lot of different species. If you have one species that can hybridize, you get lines across all those branches and it becomes a network instead of a tree. Population geneticists who want to map out the relationships of a bunch of humans or a bunch of dogs or a bunch of tulips or any one species, they don’t use trees. They use a network or they use clustering tools like we’ve used.

The state of the art in population genetics for looking at a population is a tool called PCA, or principal component analysis, that gives you this scattered plot where you see all these little dots and you can kind of see how they’re positioned with respect to each other. Usually, those are done in two dimensions, but you can project them into three dimensions and you get more information. People have done that. People have also made those network lines that you see on the galaxy, which is a different way of looking at the relationships. No one’s ever combined them, and no one’s ever made it three dimensional and made it interactive. We just took those basic tools from population genetics and we tried to make a version that was fun for normal people to play with. If it was any other subject, it’d be too science-y for people to deal with, but because it’s cannabis and because breeders and growers care so much about the history of this plant, I actually think it’s going to be one of the first times that non-scientists have been able to really geek out on genetics because this is a community that cares about genetics.

Shango Los: You know, they say that cannabis is the gateway to horticulture. Maybe now, because of the technology, cannabis is becoming the gateway to genetics for folks too because you’re right, people care about this plant like none other. One more question before we go to the break, you mentioned a scatter plot. I’ve seen scatter plots when they’re comparing or relating many different species and you say that we are looking at one species that’s been cross-hybridized with itself so many times. What would the scatter plot look like for cannabis? Would it all be scattered so close together that it’d make a single blob in the middle of the page because it’s also hybridized?

Mowgli Holmes: Well, the galaxy is the scatter plot, it’s just stretched into three dimensions. Imagine if you compressed it into two dimensions. It would be messier, but because it’s three dimensions, you can spin it around and look at it from different angles. That is the scatter plot. It’s just presented in a way that makes it so you can actually climb around inside of it.

One thing that I should say is that people have … It’s just a fancy version of, like I said, of tools that population geneticists use. We’re already talking to people about using it for cocoa, sorry, I mean cacao and coffee varieties, and we just talked with a group from Stanford that has done a population genetics study of a whole human population. They’re going to use the galaxy to visualize their data, because it’s just a good tool for looking at how populations are structured.

Shango Los: Right on. Cool. Well, when we get back from the commercial break, we’re going to talk about some of the commercial applications of this. You are listening to the Ganjapreneur.com podcast.

As a cannabis entrepreneur, you know how challenging recruiting quality talent can be. Your day’s already busy enough, and yet there is an ever growing pile of resumes on your desk and your team is begging you to hire more help. Hiring the right person can make a profound impact on your company. There’s no reason that you have to suddenly be an expert hiring manager, not when there is Viridian Staffing. Viridian Staffing recruits solely for adult use cannabis, medical marijuana, and hemp companies and those that service them.

Viridian Staffing’s recruiters each have over ten years of experience, and they will use that experience to recruit the kind of employees that will make you look good. Whether you’re looking for a master grower, extractor, grow room support, or trimming, Viridian can find an appropriate person in your area. They can even recruit administrative or graphic design professionals who may not need cannabis experience. Because you are a startup, you may also need human resources help for a while. Viridian Staffing can make sure that your HR files are complete and keep you out of trouble with state and federal employment requirements. Because the cannabis industry is booming, cannabis recruiting companies are popping up all over the country, but good marketing does not mean good recruiting. Some of the recruiting shops that have opened are run by novices who do not yet have a thorough understanding of employment law and the complexities of hiring for cannabis. Don’t hire an amateur to find you a professional. Consider Viridian Staffing to make that stack of resumes disappear and complete your team with exactly the hire you were hoping for. You can find out more at ViridianStaffing.com. That’s V-I-R-I-D-I-A-N Staffing.com.

Now, back to the show.

Welcome back. You are listening to the Ganjapreneur.com podcast. I’m your host, Shango Los and our guest this week is Mowgli Holmes, co-founded and chief science officer and Phylos Bioscience.

Right before the break, we were talking about how some of these different industries are excited about using your 3D mapping tool, the galaxy, for whatever industry they’re working in. Let’s riff a little bit on some of the commercial applications across the board for the family tree of cannabis that you’re putting together. The first thing that jumps to mind is intellectual property. We had Reggie Gaudino from Steep Hill on the show, I don’t know, maybe eight weeks ago, talking about how for breeders, they’re going to have to get to an F9 in order to patent something with the federal government when that time comes. It seems to me that your family tree is going to be really useful for all types of breeders who are going to want to show their place on the tree and therefore try to own it with a patent and then license it. Is that an accurate understanding?

Mowgli Holmes: I think some people see it like that, but we don’t see it like that.

Shango Los: All right, how do you see it, then?

Mowgli Holmes: Right now, the conversation about IP and patents in the world of cannabis is heating up in a big way, and people are really striking around, trying to figure out what to do about it. Me and Reggie have taken very different approaches to how to deal with it, but I actually got to see Reggie last week and we spent a few hours talking about it. Our approaches aren’t as different as we thought they were, but they are a little different.

We actually see the galaxy as a tool to block plant patents, rather than to enable them. What everybody’s worried about is the coming invasion of big ag and the potential threat from them patenting lots of stuff and maybe restricting access to it. Reggie’s approach was let’s get your stuff sequenced and people can try to patent their own stuff and then Big Ag won’t be able to patent it or grow it. Our approach was let’s get all this old stuff sequenced and use that as proof that it’s in the public domain so that no one can ever patent it. Those are two different and valid approaches. Our feeling is that plant patents aren’t going to be a good tool in this industry.

First of all, all of this old stuff is in the public domain, it has to be. Legally, it is in the public domain. If stuff has been circulating and is so old, it cannot be patented. We’re giving all of the data that we can give to a nonprofit that we’ve been working with called the Open Cannabis Project. They’re just going to sort of keep track of the database and make sure that all of the existing strains have some evidence showing that they’re in the public domain, they’ve been sold and they’ve been circulated, and therefore, according to patent law, they can’t be patented. Only brand new things that haven’t been sold, ever, can be patented. That wouldn’t stop someone from coming in and taking something old and renaming it and pretending it was new and trying to patent it, because no one’s been watching cannabis. USPTO has not been watching it. There’s no proof that things are in the public domain. We wanted to use all of the sequence data as proof that things are in the public domain. We got a lot of push back, especially from Northern California, because a lot of growers said, “Well, I want to patent my stuff.” Our answer to that has been, “If it’s old or you sold it, you can’t patent it. If you make something new, that’s a different story.”

Right now, the government’s not supporting cannabis patents, though it looks like they may start to. They granted one utility patent already, and they may start to grant plant patents. Our general position has been that everyone needs to accept that the stuff that’s out there now can’t be patented and we should be fighting to make sure it’s in the public domain and no one tries to patent it illegally. Then, going forward, we do want breeders to find a way to get paid because they’ve done incredible work and we want them to keep doing incredible work. But there is no structure that protects them right now, and we don’t know how to solve that problem, but we do think that plant patents won’t be the way to do it because plant patents are expensive and difficult to get and hard to defend and don’t work well in fast moving, innovative industries like this. They generally favor big corporations and they do not generally turn out to be a tool for little guys. That’s our feeling. We feel like people should keep their brand new stuff proprietary, hold it close, and as a community we should figure out how to support breeders in getting licensing fees and royalties. It’s a really, really tough question, and I don’t think the USPTO’s going to be the answer for the community, but we’ll see.

Shango Los: I got to say that I’m surprised and actually pretty stoked by your answer, because I came into this interview expecting you to say that, “Yes, we are making this key to the past of cannabis genetics,” and because of that, you’re creating the bed for Big Ag and Big Pharma to come in and patent these genetics because they will be able to do so faster than every man, and to build on that. It’s true, you know, anything that already exists and is being sold can’t be patented because it’s already out in a market. This leads me to the question of, what if you were to take two, say, land races and cross those and let’s say that was done for the first time by a pharmaceutical company, would they then use the galaxy to show that this cross doesn’t exist, and then their hope would be then to use that evidence that their cross is unique and therefore could be patented? Is that how the exercise is thought through?

Mowgli Holmes: The existing apparatus for patenting plants is there’s a big existing structure in place. You can get three different kids of IP protection over plants. There’s enforcement, there’s regulation. Once all those things come into play for cannabis, if they do, the galaxy won’t be part of that. In fact, you can use DNA sequences to prove that something has been around and is in the public domain, but you’ve never had to use DNA sequences in order to patent things because we never had them before. It’s a bunch of different criteria that Big Ag uses to patent plants.

We don’t think the galaxy will be a useful tool to help little guys patent things or big companies patent things. If anybody makes a brand new cross and can prove that it is truly unique and different and novel, and if they want plant variety protection, they need to prove that it’s true breeding, if they can prove all those things then, in theory, they can get a patent if the USPTO’s willing to grant that kind of patent. They wouldn’t need the galaxy at all. The galaxy is really a tool for the industry to see what they have and understand where things came from and really, ultimately, identify what they’re selling to people. Right now, there’s total confusion in the strain naming world, and if you look at the galaxy, there’s one big cluster of Girl Scout cookies and varieties, but there’s a bunch of other Girl Scout cookies all over the galaxy, they’re in different places, so by definition they’re genetically distinct. Which one is the real one? It’s answering those kind of questions, which we hope to be able to do with the galaxy so that in the future rec users and medical patients can get the same stuff over and over and over, instead of wandering into dispensaries and getting something different every time. It’s really much more a tool to bring consistency and knowledge to the industry than to help people with their IP issues.

Shango Los: Right on. I’ve got one more question on this kind of corporate science topic, before we move on to some real world medical applications for your technology. That is, we did a show a while back where Tyler Marquardt made the case for GMO cannabis. I’m sure that the genetic insertion folks are kind of beside themselves, excited to get their hands on the galaxy to help them figure out where they want to work. What are your thoughts on genetic insertion GMO?

Mowgli Holmes: Yeah, so again, the galaxy is not a good tool for that. I mean, if you asked a scientist, they would tell you. What you need to do genetic modification is a big, detailed, annotated version of the entire cannabis genome. A lot of groups, including us, are working on that and we do want to make that public. That would be the public resource that would help people understand genes and help with breeding, and it would also help people do genetic modification. We don’t support that. We don’t support most of the things that big ag companies do in terms of agriculture. We don’t like pesticide use, we don’t like monoculture, we don’t like restrictive plant patents, and we definitely don’t think that the cannabis community wants GMO cannabis. We think that modern plant breeding tools actually are so powerful that you can make naturally bred plants with whatever traits you want, without cutting and splicing genes back and forth. I think breeding is the way to make new plants, and I think that if people start doing GMO cannabis, it’s going to be … I just don’t think this community wants that. I think we really want plants to be bred naturally.

Shango Los: Right on. Cool. We’re going to take one more commercial break. When we get back, we’re going to talk a little bit more about breeding for specific treatment of ailments. We’ll be right back. You are listening to the Ganjapreneur.com podcast.

The Ganjapreneur.com podcast is listened to by tens of thousands of cannabis entrepreneurs and enthusiasts every single week. These folks are most likely your target customers, and we’d like to introduce you to each other. Our down to earth and information rich commercial breaks can deliver your message to the cannabis business community and others who just find relief in getting high.

If you want to reach out and connect with our audience in the most personal way that we can offer, go ahead and drop us an email at grow@ganjapreneur.com, and we can talk about you becoming a commercial sponsor of the podcast. Thanks for listening and being part of the Ganjapreneur family. Now back to the show.

Welcome back. You are listening to the Ganjapreneur.com podcast. I’m your host, Shango Los, and our guest this week is Mowgli Holmes, co-founder and chief science officer at Phylos Bioscience.

The part that I want to end with is how the 3D galaxy map of the cannabis family tree is going to help real people. This show is really in favor of patients’ rights and the medical applications of cannabis, all the way to believing that recreational cannabis is actually medical cannabis, because it’s giving stressed out people the opportunity to get some relief from that stress.

Mowgli Holmes: Yeah, absolutely.

Shango Los: What you’re building is this beautiful thing. The galaxy is beautiful to see, it traces the genetics over history, and it’s got me thinking that there just has to be ways to apply that knowledge looking forward, putting it in the hands of breeders so that they can develop specific cultivars to address particular ailments. Is it going to be useful for breeders to do that?

Mowgli Holmes: It will be. It’s funny, I don’t want to downplay the galaxy, I think it’s a great tool, but you asked me if it would be useful for IP and I said, “Well, it’s not really good for that.” Would it be useful for genetic studies or genetic manipulations? It’s not really good for that. At the moment, it’s not really a tool for breeders either. The main thing it’s a tool for, like I said, is knowledge and bringing consistency to the industry so people can finally start to know what they’re getting. It will evolve into a tool that’s good for breeders because as we start to be able to add trait data, you can imagine a THC or a CBD heat map superimposed on the galaxy. We have lots of other kinds of data we’re going to roll out. You’ll be able to click on individual nodes and see chemical metadata for them and location data and we’ll have a geographic view showing where things came from. All of that stuff will let readers make intelligent choices about what parents to pick when they’re looking for new traits or what parents to pick when they want something but don’t have it and they want to find it nearby. All of those things will help readers.

I mean, really the way that breeding is going to work in the future is that … I mean, there’s a whole set of breeding tools that just go beyond the galaxy, that have to do with sequencing the progeny when you make a cross and looking for the right genes. Once we start to understand what all the different genes are doing, that’s a way that we can help breeders really accelerate their work. I think that’s going to be the future, and that’s what’s going to let us develop the next generation of cannabis varieties. I think the galaxy will be part of that, but it’s really a whole other set of technologies in addition that have to be rolled out. It all depends on really understanding the genome. The galaxy lets us understand the relationships, but it’s another layer of work to understand what each of the genes are doing.

We’re about to be operating under an Oregon state cannabis research license that will let us work with unlimited plant counts to do basic genetic research. We’re about to be able to start tracking down those genetic pathways. Where are the genes for pest resistance? What are the terpene metabolism pathways? Pretty soon we’ll know that stuff.

Shango Los: You know, coming into this interview, I actually thought that by simply doing the map that you’re doing that you can see those genetics as part of that process and would know them, but now I’m realizing from so many things you’re telling me that what the map is not, that actually it’s a really huge second step. The first step is yeah, we’re going to map it, and now we see the family tree, but now we have to figure out what these genetics actually do. Where is the particular genetic for this taste or this result or the one that stops shaking in Parkinson’s? First, you’re going to map the area, and then you have to go in and study what the delineations are, and it’s only at that point that you have something that’s really usable.

Mowgli Holmes: That’s right, that’s really usable for breeding, at least. Yeah, that’s absolutely well put.

Shango Los: Right on. That second step sounds like a hell of a lot more research.

Mowgli Holmes: It’s a lot of work, but I will say that … I mean, it’s scientifically the most fun project you could possibly have because scientists labor away in one little, tiny corner of their fields and there’s always thousands of other people working on everything about every organism, and here’s an organism with almost no research done on it. So much of the next phase of this basic genetic research I’m talking about is going to come so fast because we know how to do this work, we’ve known how to do it for decades, and we just haven’t done it for cannabis yet. It’s just really exciting.

Shango Los: Yeah, totally. I was talking with Robert Clark at Emerald Cup, and we were just joking around and he’s all like, “Man, it’s really great to be a scientist in an industry that people care enough to actually want to talk to you.”

Mowgli Holmes: Yeah, it’s amazing. It’s amazing. It’s a brand new scientific field, and normal people actually care about it. It’s incredible.

Shango Los: Right on. Well, that’s all the time we have for today. Thanks so much for being on the show, Mowgli. I really enjoyed it.

Mowgli Holmes: Yeah, thank you. It was fun. I’ll talk to you soon.

Shango Los: Mowgli Holmes is co-founder and chief science officer at Phylos Bioscience. To find out more, you can go to their website at Phylosbioscience.com. That’s Phylos, P-H-Y-L-O-S Bioscience.com. You can also watch Mowgli’s fabulous slide presentation at Tech Fest Northwest by searching Mowgli Holmes Tech Fest on YouTube.

If you want more info on cannabis genetics, check out our back catalog interviews with Tyler Marquardt, of Allele Seeds, making the case for GMO cannabis, and also Reggie Gaudino, speaking on patenting strains and botanical intellectual property. You can find more episodes of the Ganjapreneur podcast in the podcast section at Ganjapreneur.com and in the Apple iTunes store. On the Ganjapreneur.com website, you will find the latest cannabis news, product reviews, and cannabis jobs updated daily, along with transcriptions of this podcast. You can also download the Ganjapreneur.com app in iTunes and Google Play. For info on me and where I will be speaking, you can go to ShangoLos.com.

Do you have a company that wants to reach our national audience of cannabis enthusiasts? Email grow@ganjapreneur.com to find out how. Today’s show was produced by Michael Rowe. I am your host, Shango Los.

End


Louisiana Legislature Passes Medical Cannabis Proposal

The Louisiana Senate voted on Monday to approve changes made by the House to a medical cannabis proposal that is now headed to Gov. John Bel Edwards’ desk. The governor is expected to sign the bill — making Louisiana the 25th U.S. state to establish a comprehensive medical marijuana program — according to a NOLA.com report.

The bill was proposed by Sen. Fred Mills (R-Parks), a St. Martin Parish pharmacist.

If the governor signs the law, two schools — Louisiana State University and Southern University — may choose to opt into the role of producing marijuana for the program. If neither does, however, production rights for medicinal cannabis in Louisiana will be transferred to the private sector.

The program would allow for ten specialized medical marijuana pharmacies throughout the state.

Both the Louisiana Sheriff’s Association and the Louisiana District Attorneys Association oppose the legislation because of a change that means doctors will only be “recommending” cannabis, not “prescribing” it — this means doctors will no longer be jeopardizing their DEA license, which prohibits the prescription of a Schedule 1 substance, by participating in the medical marijuana program.

The House of Appropriations Committee passed separate legislation on Monday, which would grant a 7 percent cut from medical marijuana sales to the Department of Agriculture to aid it in regulating the program.

End


Gov. John Hickenlooper signing a bill into law in 2013.

Legalization is Working, Colorado’s Governor Confirms

Colorado Governor John Hickenlooper has changed his tune on legal cannabis from one of open doubtfulness to a significantly more optimistic stance, according to an LA Times report.

During a panel discussion at the Milken Institute Global Conference held recently in Los Angeles, Gov. Hickenlooper said that Colorado’s move to legalize is “beginning to look like it might work.”

The governor was a vocal critic of the law during the 2012 election, citing concerns over public safety and the potential for increased teenage use. At the time, he called the move “reckless” — a statement he later downgraded to “risky.” The governor also said that if he had been granted the power to undo the 2012 decision by Colorado voters, he would have done so.

However, “If I had that magic wand now, I don’t know if I would wave it,” Gov. Hickenlooper said.

According to Andrew Freedman, director of marijuana coordination for Colorado, the governor’s change in opinion is due to a growing sense of optimism regarding the industry’s regulatory infrastructure. “In the short run, there have been a lot fewer public safety and health issues than the governor feared in the beginning,” Freedman said. “In the beginning, we had problems with edibles and hash oil fires but now, for the most part, Colorado looks a lot like it did before legalization.”

According to Mason Tvert, spokesman for the Marijuana Policy Project, “The predictions of fire and brimstone have failed to materialize. Most Coloradoans, including the governor, recognize that the law is working.”

The state collected more than $135 million in cannabis taxes during 2015, $35 million of which was earmarked for school construction projects.

End


A collection of clones on display in a California cannabis dispensary.

Online Cannabis Entrepreneur Summit Blasts Off This Weekend

The first virtual Cannabis Entrepreneur Summit is taking place this weekend, May 21-22. The event, hosted by Green Flower Media, will bring cannabis experts and industry professionals together for a series of educational seminars about the business and science of marijuana — all live-streamed and free-to-watch anywhere for anyone who registers for the event.

“Whether you’re thinking about entering the industry, you already have a growing business in the space, or you’re an interested investor, this live-streamed online Summit will give you the guidance and direction you need to make your dent in the blossoming cannabis universe,” the event page reads.

Our own Shango Los, host of the Ganjaprenuer.com Podcast, will be presenting a segment on online marketing strategies to help cannabis businesses grow their company and build a strong brand. “It is an honor to share a stage with so many of the cannabis industry’s top business minds,” Shango said. “By working together to educate the industry as a whole, we can further solidify normalization across the country and help both patients and cannabis enthusiasts alike.”

Panel speakers will have 22 minutes to share a message with their audience.

Other notable speakers this weekend are Steve DeAngelo of Harborside Health Center, who will speak broadly on “the future of cannabis,” and Reggie Gaudino of Steep Hill Laboratories, who will discuss ways to “protect yourself and cannabis from the inevitable entry of big pharma and big agriculture.”

If you want to watch these presentations for FREE, don’t forget to register in advance for the Summit!

End


Texas GOP Adds Medical Cannabis Improvements to Party Platform

In an unprecedented win for cannabis normalization in Texas, the state’s Republican Party announced at a GOP convention last week that it was adding an expansion of the state’s medical marijuana program to the party’s political platform.

Here’s the exact language approved last week by the Texas GOP:

We call upon the Texas Legislature to improve the 2015 Compassionate Use Act to allow doctors to determine the appropriate use of cannabis to prescribed patients.

According to Heather Fazio, Texas Political Director for the Marijuana Policy Project, this is a hopeful sign.

“This confirms what we already knew: marijuana law reform is not a partisan issue,” Fazio said in a statement. “Across the board, Texans of all political persuasions acknowledge that cannabis is medicine and support the reforming of outdated policies.”

The 2015 Compassionate Use Act was passed to open up only individuals suffering from intractable epilepsy to CBD oil treatment. While this announcement is not a direct policy change, it signals that the Texas Republican Party should at least be willing to have serious discussions about how best to expand the program.

The GOP’s new-found progressive ideals, however, do not extend to the full legalization of cannabis. They also approved the following language:

We oppose legalization of illicit and synthetic drugs. We also oppose any needle exchange programs. Faith based rehabilitation programs should be considered as a part of an overall rehabilitation program.

End


Cannabis Dispensary to Replace San Francisco’s Last Gun Store

High Bridge Arms, the last gun store in San Francisco, officially shuttered its doors in October, 2015 following a long fight with city officials over regulations requiring that firearm sales be videotaped and ammunition sales be reported to police.

Now, according to a recent 7×7 report, an effort to turn the building into a medical marijuana dispensary has been filed with the city’s planning commission.

Pacific Heights resident Sean Killen founded the new dispensary, aptly named High Bridge, to be a nonprofit endeavor dedicated to enhancing its local community — a stark contrast from the location’s namesake. Killen plans to keep medicine prices low, and says he will be offering some product at no cost to his poorest patients.

High Bridge’s landlord, Mr. Takahashi, bought the building originally in 1988. Takahashi is “very happy, quite frankly, that a cannabis store is going in there,” Killen said. In fact, one clause in the dispensary’s lease draws particular attention to the building’s history: the new business “shall not use [the space] for the purposes of storing, manufacturing, or selling any explosives, flammables, or other inherently dangerous substance, chemical, thing or device.”

“We did find a lot of stray bullets in there during renovations,” joked Killen.

End


Dr. Ethan Russo: Non-Cannabis Plants Could ‘Nurture’ Endocannabinoid System

New research suggests that we can nurture some responses from our endocannabinoid system from plants other than cannabis, helping to keep it regulated and “healthy.”

According to Dr. Ethan Russo, author of “Beyond Cannabis: Plants and the Endocannabinoid System,” “numerous additional plants whose components stimulate, antagonize, or modulate the different aspects of the system” have been identified. Previous research has shown that our endocannabinoid system is responsible for our “relax, eat, sleep, protect and forget” functions, additionally performing major regulatory conditioning and maintenance functions in the brain, skin, liver, genitals, digestive tract, cardiovascular system and bone.

Russo first published the theory that some conditions, such as migraine, fibromyalgia, and irritable bowel syndrome, could be due to endocannabinoid system deficiency, in 2001 — though Russo revisited the subject in more detail in 2004. And, in 2008, subsequent research on this hypothesis (also by Russo) concluded that it is “highly likely that additional regulatory roles for endocannabinoids will be discovered” for modulating these systems and potentially treating these disorders when “modern medicine fails to cure.”

The endocannabinoid system has two cannabinoid receptors. When activated, CB1 is responsible for the psychoactive effects of marijuana when triggered by THC, while CB2 reduces pain and other inflammatory systems. However other systems have similar responses when triggered, such as TRPV1, which is triggered by capsaicin, the active ingredient in chili peppers. TRPV1 regulates temperature and pain responses and can be blocked by the non-psychoactive ingredient in cannabis, CBD. Using CBD to block TRPV1 “turns down” neuropathic pain, including; migraines, burns, chronic pelvic pain, bowel disorders, fibromyalgia and irritable bladder symptoms.

Russo notes that CBD has “not been definitively identified in other plants.”

In much the same way TRPV1 can be blocked by the introduction of CBD, the endocannabinoid system can be inhibited as well.

Carrots, for example, contain the natural pesticide and fungicide falcarinol – which has shown in studies to block cannabinoid receptors. If that caratoxin can be absorbed by the gastrointestinal tract, blocking cannabinoid receptors, it could be used as an appetite suppressant because of the role the endocannabinoid system plays in regulating our eating habits.

CBD and THC are not the only compounds in marijuana that help to modulate the endocannabinoid system. Cannabigerol, the “parent” to THC, only presents itself in trace amounts. Despite making up just a small part of cannabis DNA, cannabigerol has shown antidepressant effects in rodents and effectiveness as an antibiotic against MRSA. The compound has also been found in a flower native to South Africa, which could lead to additional research on the compound because it is not subjected to the same regulatory oversight as marijuana.

Beta-caryophyllene is another agent found in cannabis that interacts with CB2 receptors – which, due to this relationship, has anti-inflammatory properties. This compound is found in commonly used substances, such as; black pepper (up to 35 percent), lemon balm (up to 19.1 percent), cloves (up to 12.4 percent) and hops (up to 9.8 percent). Interestingly, black pepper has shown to mimic the effects of cannabis in mice at 2.5-10 mg/kg greater than placebo.

Frankincense also shows similar anti-inflammatory, antioxidant, and antiseptic effects to those found in cannabis. Additionally, it meets the “cannabinoid tetrad” – the four signs researchers use in animal experiments to determine that a substance stimulates CB1. This does not mean that frankincense can be used to get high; rather it means that it could be useful in maintaining endocannabinoid system health without cannabis.

Some varieties of terpenoid-producing herbs and other plants bearing glandular trichomes and lipids contain THC analogs but there is no evidence to conclude they have any psychoactive effect. Because these compounds – found in salvia, citrus and two types of liverworts (relatives of moss found in Japan and New Zealand) – seem to mimic THC on a molecular level, they too could be used to some effect in maintaining the health of the endocannabinoid system.

Despite the gains made in recent years, there is still a lot of work to be done in studying not only the endocannabinoid system, but what compounds could help modulate it. If some debilitating diseases are the result of a dysfunctional endocannabinoid system, as suggested, then finding ways to nurture this system could lead to potential treatments and, quite possibly, cures.

“When the substances involved may also include potentially forbidden substances resembling THC, which are subject to regulatory scheduling, the barriers to research become greater still,” Russo wrote. “…This educational deficit, born perhaps of lingering prejudice toward a plant called cannabis, must surely end soon, as it is contrary and detrimental to the potential significant contributions to public health.”

End